Colonial Trust Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Colonial Trust Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8	Closed	-$992	–	925
2023 Q2	$992	Hold	8	–	–	﹤0.01%	796
2023 Q1	$1.17K	Buy	+8	New	+$1.18K	﹤0.01%	779

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Colonial Trust Advisors's JAZZ Position: Q3 2023 in Review

Colonial Trust Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2023, closing a stake of 8 shares — an estimated $992 sold.

Colonial Trust Advisors first reported a position in JAZZ in Q1 2023 and held it in 2 quarters. The position peaked at $1.17K in Q1 2023. 484 funds tracked by Wall St. Rank hold JAZZ as of Q3 2023.

Colonial Trust Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Colonial Trust Advisors sold 8 Jazz Pharmaceuticals shares in Q3 2023, an estimated $992.
Colonial Trust Advisors first reported a position in Jazz Pharmaceuticals in Q1 2023 and held it in 2 quarters.
Colonial Trust Advisors's Jazz Pharmaceuticals position peaked at $1.17K in Q1 2023.
484 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2023.

Based on Colonial Trust Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.